Mylan

Mylan N.V.
Mylan N.V.
FormerlyMilan
Company typePublic (under Dutch law)
Nasdaq: MYL
IndustryPharmaceuticals
Founded1961; 63 years ago (1961) in White Sulphur Springs, West Virginia, United States
FoundersMilan Puskar
Don Panoz
DefunctNovember 16, 2020; 3 years ago (2020-11-16)
FateMerged with Upjohn to form Viatris
SuccessorViatris
Headquarters
Hatfield, Hertfordshire
,
United Kingdom
ProductsGeneric and specialty pharmaceuticals and active pharmaceutical ingredients
Divisionssee Operations
Websitewww.mylan.com Edit this on Wikidata
Footnotes / references
[1]

Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris.[2] Previously, the company was domiciled in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK[3] and a "Global Center" in Canonsburg, Pennsylvania, US.

In 2007, the company acquired a controlling interest in India-based Matrix Laboratories Limited, a top producer of active pharmaceutical ingredients (APIs) for generic drugs,[4] and the generics business of Germany-based Merck KGaA.[5] Through these acquisitions, the company grew from the third-largest generic and pharmaceuticals company in the United States to the second-largest generic and specialty pharmaceuticals company in the world.[6]

Mylan went public on the OTC market in February 1973.[7] It was listed on the NASDAQ,[8] and its shares were a component of the NASDAQ Biotechnology[9] and the S&P 500 indices.[10]

The company was founded in 1961 and developed and produced medicines for a wide range of medical disciplines, including oncology, anaphylaxis, antiretrovirals, cardiovascular, respiratory, dermatology, immunology, anesthesia and pain management, infectious disease, gastroenterology, diabetology/endocrinology, and women's healthcare.[11]

  1. ^ "FORM 10-K".
  2. ^ Gough, Paul J. (November 16, 2020). "After nearly 60 years, Mylan makes way for Viatris". Pittsburgh Business Times. Retrieved December 10, 2020.
  3. ^ Mylan NV 10-K for the Fiscal Year Ended December 31, 2015
  4. ^ "Mylan buys part of drug maker". American City Business Journals. December 18, 2006.
  5. ^ "Mylan Laboratories To Acquire Generics Business Of Merck KGaA For 4.9 Billion Euros". Medical News Today. May 26, 2007. Archived from the original on February 24, 2008. Retrieved January 28, 2010.
  6. ^ "Pharmaceutical giants tracking Mylan's prosperity". The Pittsburgh Tribune-Review. August 13, 2008. Archived from the original on September 8, 2008.
  7. ^ "History of Mylan Laboratories Inc. – FundingUniverse". www.fundinguniverse.com. Retrieved June 11, 2018.
  8. ^ "Mylan N.V." MarketWatch. Retrieved June 11, 2018.
  9. ^ "iShares Nasdaq Biotechnology Index Fund (IBB)". NASDAQ.com. Retrieved June 11, 2018.
  10. ^ "Market Realist". marketrealist.com. October 5, 2017. Retrieved June 11, 2018.
  11. ^ "Therapeutic Innovation". www.mylan.com. Retrieved August 8, 2018.